Testosterone Enanthate: Comprehensive Research Overview

Document Version: 2.0 Last Updated: January 2025 Classification: HRT Research Paper - Schedule III Controlled Substance Enhancement: Added Goal Archetype Integration, Age-Stratified Dosing, Comprehensive Drug Interactions, Bloodwork Impact Mapping, Protocol Integration sections

Goal Relevance:

• Boost testosterone levels for improved energy and vitality
• Support muscle growth and strength for fitness goals
• Enhance libido and sexual wellness for improved relationships
• Aid in recovery from low testosterone conditions like hypogonadism
• Assist in managing symptoms of delayed puberty in young males
• Provide hormone therapy support for transgender men
• Help with body composition improvements in specific medical conditions like HIV-associated wasting

1. Executive Summary + Regulatory Classification

Overview

Testosterone enanthate is a synthetic C17β heptanoate (enanthate) ester of testosterone, the primary endogenous androgen in males. It is marketed under brand names including Delatestryl (discontinued in US, though generics available) and Xyosted (subcutaneous autoinjector approved 2018). Testosterone enanthate is an androgen and anabolic steroid (AAS) medication used primarily for testosterone replacement therapy in men with hypogonadism, delayed puberty in boys, and metastatic breast cancer in women.

Primary Classification

• Chemical Class: Androstane steroid, testosterone ester
• Pharmacological Class: Androgen; anabolic-androgenic steroid (AAS)
• Therapeutic Class: Hormone replacement therapy (HRT) for male hypogonadism

Regulatory Status Summary

FDA-Approved Indications

According to the official FDA label for Delatestryl, testosterone enanthate is indicated for:

For Males:

1. Replacement therapy in conditions associated with deficiency or absence of endogenous testosterone:
   • Primary hypogonadism (congenital or acquired): Testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter syndrome, chemotherapy, or toxic damage
   • Hypogonadotropic hypogonadism (congenital or acquired): Gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation
2. Delayed puberty in carefully selected males with clearly delayed puberty

For Females:

• Metastatic mammary cancer: May be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are one to five years postmenopausal

Limitations of Use

Safety and efficacy in men with "age-related hypogonadism" have not been fully established per FDA guidelines.

Off-Label Uses

• Gender-affirming hormone therapy for transgender men (widely used off-label, considered standard of care)
• Body composition improvement in HIV-associated wasting
• Fertility preservation when combined with HCG

Brand Names & Manufacturers

• Delatestryl (Endo Pharmaceuticals) - Brand discontinued in US but generic equivalents available
• Xyosted (Antares Pharma) - FDA-approved subcutaneous autoinjector (2018)
• Generic formulations from multiple manufacturers (Eugia USA LLC, others)
• Compounded - Available from 503A/503B compounding pharmacies

2. Chemical Structure & Pharmacology

Chemical Identity

Chemical Structure

Testosterone enanthate is the C17β heptanoate (7-carbon) ester of testosterone. The enanthate ester extends the half-life of testosterone by slowing its release from the intramuscular or subcutaneous depot into systemic circulation.

Pharmacology Classification

Testosterone enanthate is a prodrug of testosterone and is an androgen and anabolic-androgenic steroid (AAS) that acts as an agonist of the androgen receptor (AR). Esterase enzymes break the ester bond through hydrolysis, releasing free testosterone and enanthic acid.

Ester Comparison: Enanthate vs Cypionate

The distinction between enanthate and cypionate lies exclusively in the ester:

• Enanthate: Heptanoate ester with 7 carbon atoms
• Cypionate: Cyclopentylpropionate ester with 8 carbon atoms

Cypionate has a slightly longer half-life (~8 days) compared to enanthate (~5-7 days), though this 1-2 day practical difference becomes negligible with twice-weekly or more frequent injection protocols.

Relationship to Endogenous Testosterone

Once the enanthate ester is cleaved by esterases, the remaining molecule is bioidentical testosterone indistinguishable from endogenous testosterone.

Goal Archetype Integration

Testosterone enanthate serves as a foundational hormone that supports multiple health optimization goals. Understanding how TRT integrates with specific objectives helps clinicians and patients align therapy with individual outcomes.

Primary Goal Alignment

Fat Loss Goals

Primary Mechanisms:

• Increases basal metabolic rate by 5-15% through enhanced lean mass
• Improves insulin sensitivity, reducing fat storage tendency
• Promotes lipolysis through androgen receptor activation in adipose tissue
• Reduces visceral fat accumulation (the most metabolically dangerous fat depot)

Protocol Considerations:

• Higher estradiol conversion in obese patients may require aromatase inhibitor (AI) consideration
• Synergistic effects when combined with GLP-1 agonists (see Protocol Integration section)
• Target mid-to-high normal testosterone (500-700 ng/dL) for optimal metabolic effects
• More frequent, smaller doses (twice weekly) reduce estradiol spikes that can promote fat retention
• Enanthate's slightly shorter half-life may benefit from twice-weekly dosing for stable levels

Expected Outcomes:

• 3-6% reduction in body fat over 6-12 months (with consistent training/nutrition)
• Preferential loss of visceral over subcutaneous fat
• Improved body composition even without significant scale weight changes

Muscle Building Goals

Primary Mechanisms:

• Direct activation of androgen receptors in skeletal muscle
• Increased nitrogen retention and protein synthesis
• Enhanced satellite cell activation and myonuclear addition
• IGF-1 pathway stimulation (synergistic with GH secretagogues)
• Improved recovery capacity and reduced catabolism

Protocol Considerations:

• Target upper-normal testosterone levels (600-800 ng/dL) for hypertrophy goals
• Ensure adequate protein intake (1.6-2.2 g/kg body weight)
• Monitor hematocrit closely as training intensifies oxygen demand
• Consider split dosing (2x/week) for more stable anabolic environment
• Enanthate's peak at 24-48 hours may be timed with heavy training days

Expected Outcomes:

• 2-5 lbs lean mass gain in first 6 months (hypogonadal men)
• 10-20% strength increases in major lifts over 12 months
• Improved training recovery and reduced DOMS

Longevity & Healthspan Goals

Primary Mechanisms:

• Maintains bone mineral density (reduces fracture risk 30-50%)
• Preserves lean mass (sarcopenia prevention)
• Supports cardiovascular function (TRAVERSE trial showed no increased MACE risk)
• Cognitive protection through neurosteroid effects
• Reduces all-cause mortality in hypogonadal men (observational data)

Protocol Considerations:

• More conservative dosing targeting mid-normal range (400-600 ng/dL)
• Prioritize stable levels via SQ weekly or twice-weekly protocols
• Vigilant cardiovascular monitoring in patients with risk factors
• Annual DEXA scans for bone density in men >50
• Balance testosterone benefits against polycythemia risk

Expected Outcomes:

• Maintained functional capacity into later decades
• Reduced risk of osteoporotic fractures
• Sustained cognitive function and mood stability
• Improved quality of life metrics

Healing & Recovery Goals

Primary Mechanisms:

• Enhanced collagen synthesis in connective tissues
• Improved wound healing through angiogenesis promotion
• Reduced systemic inflammation (lowers CRP, IL-6)
• Accelerated muscle repair post-injury
• Synergistic with growth hormone and healing peptides

Protocol Considerations:

• Adequate testosterone is prerequisite for optimal peptide response
• Consider temporary dose increase during acute recovery phases (under supervision)
• Monitor for fluid retention which can affect surgical sites
• Coordinate with surgical team regarding perioperative management

Expected Outcomes:

• 20-40% faster recovery from musculoskeletal injuries
• Improved surgical wound healing
• Reduced rehabilitation timeline
• Better response to regenerative therapies (PRP, stem cells)

When Testosterone Enanthate Makes Sense

• Patient prefers weekly (vs biweekly) injection schedule
• International patients (enanthate more common outside US)
• Cost considerations (generic enanthate widely available)
• Patient has had good response to enanthate previously
• Xyosted subcutaneous autoinjector preferred for convenience

When to Choose Something Else

• Patient prefers less frequent injections (cypionate slightly longer half-life)
• Sesame oil allergy (most enanthate in sesame oil; some cypionate in cottonseed)
• Patient has had better response to cypionate previously
• Insurance/formulary considerations favor cypionate

3. Mechanism of Action (Tissue-Specific)

Primary Mechanism

Free testosterone is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor (AR), or be reduced to 5α-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5α-reductase.

The molecular process involves:

1. Cellular Uptake: Free testosterone crosses cell membrane
2. Androgen Receptor Binding: Testosterone binds directly to AR
3. DHT Conversion: Alternatively, conversion to DHT (2.5× greater AR affinity)
4. Nuclear Translocation: Steroid-receptor complex translocates to nucleus
5. Gene Transcription: Binds to hormone response elements (HREs), initiating transcription

Tissue-Specific Effects

Direct Androgen Receptor Activation

• Muscle protein synthesis and hypertrophy
• Bone mineralization and density maintenance
• Erythropoiesis stimulation in bone marrow
• Libido and sexual function

Conversion to DHT (via 5α-Reductase)

• Prostate growth and function
• Male pattern hair growth (facial, body)
• Sebum production and acne
• Male pattern baldness (androgenic alopecia)

Conversion to Estradiol (via Aromatase)

• Bone health and epiphyseal plate closure
• Lipid metabolism regulation
• Mood regulation and neuroprotection
• Negative feedback on hypothalamic-pituitary axis

4. Pharmacokinetics & Formulation Comparison

Absorption

Route: Intramuscular (IM) injection into gluteal muscle, or subcutaneous (SQ) injection (Xyosted)

Depot Formation: Slowly absorbed from oil depot in muscle or subcutaneous tissue, providing sustained release

Bioavailability: Nearly 100% from parenteral administration (avoids first-pass hepatic metabolism)

Distribution

• Protein Binding: ~98% bound to plasma proteins
  • SHBG: ~40-45%
  • Albumin: ~55%
  • Free testosterone: ~2-3% (biologically active)
• Volume of Distribution: Extensive; distributes to all tissues

Metabolism

• Primary Site: Liver
• Pathways:
  • Esterase cleavage of enanthate ester to release free testosterone and enanthic acid
  • 5α-reduction to dihydrotestosterone (DHT)
  • Aromatization to estradiol (E2)
  • Conjugation to glucuronides and sulfates
• Active Metabolites: DHT (more potent androgen), estradiol (estrogenic effects)

Elimination

• Half-Life: 4.5 days (elimination half-life); mean residence time 8.5 days when used as depot IM injection
• Time to Peak (Tmax): 24-48 hours after IM injection
• Steady State: Achieved after 3-4 injections
• Excretion: Metabolites excreted primarily in urine (~90%), small amounts in feces

Pharmacokinetic Comparison: Enanthate vs Cypionate

The primary pharmacokinetic difference is half-life: cypionate ~8 days per FDA labeling versus enanthate 4.5-7 days, translating to a 1-2 day practical difference that becomes negligible with twice-weekly or more frequent injection protocols.

Xyosted Subcutaneous Pharmacokinetics

Xyosted is formulated for subcutaneous administration using a disposable autoinjector designed for once-weekly self-administration. The subcutaneous route provides more stable testosterone levels with lower peak-to-trough ratios compared to traditional IM dosing.

5. Clinical Dosing Guidelines (FDA-Labeled + Off-Label)

FDA-Labeled Dosing

Delatestryl (IM Injection - Discontinued Brand)

Male Hypogonadism:

• 50-400 mg IM every 2-4 weeks
• Dose adjusted according to patient response and appearance of adverse reactions

Delayed Puberty (Males):

• 50-200 mg IM every 2-4 weeks for a limited duration (e.g., 4-6 months)

Metastatic Breast Cancer (Females):

• 200-400 mg IM every 2-4 weeks

Xyosted (Subcutaneous Autoinjector)

Starting Dose: 75 mg subcutaneously in the abdominal region once weekly

Available Strengths: 50 mg, 75 mg, or 100 mg in 0.5 mL solution

Dose Adjustment: Based upon total testosterone trough concentrations (measured 7 days after most recent dose) obtained following 6 weeks of dosing and periodically thereafter

Endocrine Society Guidelines

From the 2018 Endocrine Society Clinical Practice Guideline:

• Testosterone therapy recommended in hypogonadal men to induce and maintain secondary sex characteristics
• Diagnosis requires symptoms/signs of testosterone deficiency AND unequivocally and consistently low serum testosterone levels

Contemporary Dosing Protocols

Standard IM Protocol

• Most Common: 100 mg IM once weekly, or 200 mg every 2 weeks
• Historical Regimens: 100 mg weekly, 200 mg every 2 weeks, 300 mg every 3 weeks, or 400 mg every 4 weeks
• Optimal Frequency: Weekly injections are optimal to minimize supranormal peaks; administration every 2-3 weeks leads to large peaks and troughs

Subcutaneous Protocol (Generic, Off-Label)

• Typical Dose: 50-100 mg SQ weekly or twice-weekly
• Advantages: More stable levels, reduced peak-to-trough fluctuations, ease of self-administration

Xyosted Protocol (FDA-Approved SQ)

• Starting: 75 mg SQ weekly
• Range: 50-100 mg SQ weekly based on trough testosterone levels

Population-Specific Adjustments

Elderly Patients (≥65 years)

• Start with lower doses due to slower metabolism
• Increased monitoring for cardiovascular and prostate risks
• Gradual dose titration recommended

Obese Patients (BMI >30)

• May require higher doses due to increased aromatization to estradiol in adipose tissue
• Potentially 25-50% dose increase may be necessary
• Monitor estradiol levels closely

Gender-Affirming Hormone Therapy

• Typical Range: 50-100 mg IM weekly, or 100-200 mg IM every 2 weeks
• Target Levels: 400-700 ng/dL (mid-normal male range)
• Subcutaneous Option: 50-100 mg SQ weekly

Age-Stratified Dosing Guidelines

Age significantly influences testosterone metabolism, receptor sensitivity, and risk profiles. These guidelines provide age-specific starting doses and monitoring considerations. Note: Due to enanthate's slightly shorter half-life compared to cypionate, some patients may benefit from more frequent dosing.

Ages 20-35 Years

Clinical Context:

• Uncommon to require TRT in this age range without clear pathology
• Primary causes: Klinefelter syndrome, testicular injury, pituitary tumors, prior chemotherapy
• Must rule out reversible causes before initiating TRT
• Fertility preservation is a major consideration

Starting Dose Recommendations:

Key Considerations:

• Fertility: Add HCG 500-1000 IU 2-3x/week if fertility desired
• Higher baseline metabolic rate may require dose adjustment
• Monitor for supraphysiological peaks (more sensitive to elevation)
• Rule out anabolic steroid abuse as cause of low T (suppressed HPTA)
• Ensure thorough workup including pituitary MRI if secondary hypogonadism

Target Levels: 500-700 ng/dL (mid-normal range)

Ages 35-50 Years

Clinical Context:

• Most common age for TRT initiation
• Mix of primary and secondary hypogonadism
• Often concurrent with metabolic syndrome, obesity
• Career and family considerations for consistent therapy

Starting Dose Recommendations:

Key Considerations:

• Cardiovascular risk assessment before initiation
• Higher rates of estradiol conversion (especially if BMI >30)
• May need aromatase inhibitor if E2 >50-60 pg/mL with symptoms
• Sleep apnea screening recommended
• PSA baseline mandatory; family history of prostate cancer requires careful evaluation

Target Levels: 500-700 ng/dL

Ages 50-65 Years

Clinical Context:

• "Late-onset hypogonadism" increasingly common
• Often overlaps with cardiovascular disease, diabetes
• Prostate health becomes primary concern
• Balance symptom relief with safety monitoring

Starting Dose Recommendations:

Key Considerations:

• Mandatory baseline PSA and digital rectal exam
• Cardiovascular evaluation including lipid panel, blood pressure
• More frequent monitoring initially (every 6-8 weeks until stable)
• Lower threshold for hematocrit intervention (>52% warrants attention)
• Consider bone density evaluation if not recently performed
• Increased polycythemia risk; consider more frequent phlebotomy monitoring

Target Levels: 450-600 ng/dL (lower target acceptable if symptomatic improvement achieved)

Ages 65+ Years

Clinical Context:

• Highest benefit-to-risk consideration required
• Concurrent medications likely (drug interactions)
• Reduced renal and hepatic clearance
• Fall prevention and functional independence are key goals

Starting Dose Recommendations:

Key Considerations:

• Extended monitoring intervals during titration
• Prostate monitoring every 3-6 months initially
• Hematocrit monitoring more frequent (baseline polycythemia more common)
• Assess fall risk (testosterone can affect balance during adjustment)
• Cardiovascular comorbidities require careful risk-benefit discussion
• Cognitive function assessment at baseline
• Bone density improvement may be most significant benefit
• Lower target levels acceptable: Quality of life improvement at 400-500 ng/dL often sufficient

Target Levels: 400-550 ng/dL

Age-Stratified Dosing Summary Table

Sex-Specific Considerations

Males:

• Standard dosing as outlined above
• Monitor for gynecomastia, especially in higher BMI patients
• Testicular atrophy expected with exogenous testosterone
• Fertility impact is reversible in most cases with HCG or therapy cessation

Females (Off-Label, Gender-Affirming Care):

• Starting dose: 25-50 mg SQ weekly or 50 mg IM every 2 weeks
• Target levels: 400-700 ng/dL (mid-male range)
• Monitor for virilization effects (voice deepening is often irreversible)
• Clitoral enlargement, increased body hair expected
• Menses typically cease within 3-6 months
• Monitor hematocrit (lower threshold for intervention than males)

6. Pivotal Clinical Trials & Evidence

TRAVERSE Trial (2023) - Cardiovascular Safety

Note: TRAVERSE primarily studied testosterone gel, not enanthate specifically, but findings apply to all testosterone formulations

Key Findings:

• Testosterone therapy NOT associated with increased risk of major adverse cardiovascular events (MACE) compared to placebo
• Resolved long-standing FDA concerns about cardiovascular safety

Polycythemia and Cardiovascular Risk (2022)

Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of MACE and VTE

Study Design: Retrospective cohort study of men on testosterone therapy

Key Findings:

• Men with polycythemia had higher risk of MACE/VTE (5.15%) than men with normal hematocrit (3.87%)
• Odds ratio 1.35 (95% CI 1.13-1.61, p <0.001)
• Developing polycythemia is an independent risk factor for MACE and VTE in first year of therapy
• Testosterone treatment associated with five-times higher risk of polycythemia

Clinical Implication: Hematocrit monitoring every 3 months recommended; intervention at ~54% threshold

Xyosted Post-Market Safety and Efficacy (2021)

Post-market safety and efficacy profile of subcutaneous testosterone enanthate-autoinjector

Findings:

• Confirmed safety and efficacy in real-world clinical practice
• Increases in hematocrit to ≥55% reported for 4.2% of patients who received Xyosted for up to one year

Clinical Efficacy Evidence

It is the most widely used form of testosterone in androgen replacement therapy. Evidence supports improvements in:

• Sexual function
• Lean body mass and muscle strength
• Bone mineral density
• Mood and quality of life

Evidence Quality Summary

7. Safety Profile + Black Box Warnings

FDA Black Box Warnings

MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE)

XYOSTED can cause blood pressure increases that can increase the risk for MACE, including non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death.

ABUSE POTENTIAL

Testosterone enanthate is a Schedule III controlled substance with potential for abuse. Anabolic androgenic steroid abuse can lead to serious cardiovascular and psychiatric adverse reactions.

Polycythemia and Hematologic Effects

Erythrocytosis, or elevated hematocrit, is a common side effect of testosterone therapy in male hypogonadism.

Monitoring Requirements:

• Hematocrit should be checked at baseline, 3 months, 6 months, then every 6-12 months
• Many groups intervene when hematocrit approaches 54%
• Notify provider if hematocrit >54% or hemoglobin >17.5 g/dL

Management:

• Dose reduction
• Therapeutic phlebotomy
• Temporary discontinuation
• Switch to alternative formulation

Cardiovascular Events

Risk Factors:

• Developing polycythemia while on testosterone therapy is an independent risk factor for MACE and VTE
• Pre-existing cardiovascular disease
• Obesity, diabetes, smoking, hypertension

Reported Events:

• Myocardial infarction
• Stroke
• Venous thromboembolism (DVT, PE)
• Sudden cardiac death

Prostate-Related Effects

Benign Prostatic Hyperplasia (BPH): May worsen urinary symptoms

Prostate Cancer: Testosterone may stimulate growth of existing prostate cancer (absolute contraindication)

PSA Elevation: Monitor PSA every 6-12 months

Hepatotoxicity

Though less hepatotoxic than oral 17α-alkylated steroids, monitor liver function periodically

Other Adverse Effects

Common (>5%):

• Acne
• Injection site reactions (especially with SQ)
• Gynecomastia (due to aromatization)
• Mood changes (irritability, aggression)

Less Common:

• Edema and fluid retention
• Sleep apnea (worsening)
• Male pattern baldness
• Testicular atrophy and infertility

8. Formulation Options & Administration

Available Formulations

Intramuscular (IM) Injection Technique

Injection Site: Deep gluteal muscle (ventrogluteal or dorsogluteal), vastus lateralis (thigh), or deltoid (smaller volumes)

Needle Selection:

• Gauge: 21-23G
• Length: 1-1.5 inches (depending on body habitus)

Procedure:

1. Warm vial to room temperature
2. Draw medication using aseptic technique
3. Use Z-track method to minimize leakage
4. Inject slowly over 30-60 seconds
5. Apply pressure but do not massage
6. Rotate sites between injections

Subcutaneous (SQ) Injection Technique

Xyosted Autoinjector:

• Inject into abdominal region only
• Avoid intramuscular or intravascular injection
• Single-use device; discard after use
• Autoinjector simplifies self-administration

Generic SQ Injection:

• 25-gauge, 5/8-inch needle
• Abdominal subcutaneous tissue or anterolateral thigh
• Pinch fat, insert at 45-90 degree angle
• Inject slowly
• Rotate sites

Timing Considerations

IM Injections: Every 7-14 days depending on dose and formulation

SQ Injections (Xyosted): Once weekly on the same day each week

Optimal Injection Frequency: Weekly injections are optimal to minimize supranormal testosterone levels; administration every 2-3 weeks leads to large peaks and troughs

9. Storage & Stability

Recommended Storage Conditions

Testosterone should be kept between 68°F and 77°F (20°C to 25°C) at controlled room temperature.

Xyosted: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F)

Refrigeration - NOT Recommended

Testosterone enanthate should NOT be refrigerated or frozen. Extreme cold can affect efficacy and increase crystallization risk.

Carrier Oil Stability

Sesame oil has favorable thermal stability maintaining viscosity across 15-30°C storage ranges. It shows lower incidence of lipohypertrophy (2.1 cases/1000 injections vs 5.3 for cottonseed).

MCT oils demonstrate greater resistance to oxidation compared to seed oils such as cottonseed, grapeseed, or sesame oil, which are more prone to degradation over time.

Shelf Life

Unopened Vials: Most vials have an average shelf life of 24-36 months if stored in adequate conditions

Opened Multi-Dose Vials: Typically stable for 28 days after first puncture; consult specific product labeling

Xyosted: Single-use; no storage after opening

Light Protection

Store in opaque container to protect from light exposure, as sunlight or fluorescent light can lead to degradation.

Degradation Concerns

The primary issue with expired testosterone isn't usually the hormone molecule itself, but rather the carrier oil it's suspended in, which can oxidize over time.

10. Detailed Regulatory Status (FDA, DEA, WADA, International)

FDA Approval History

Initial Approval: 1953 for testosterone enanthate

Delatestryl (Brand): Approved but discontinued in US; FDA determined discontinuation was not for safety or effectiveness reasons

Xyosted: FDA approved 2018 as first subcutaneous testosterone enanthate autoinjector

Generic Approvals: Multiple generic manufacturers (Eugia USA LLC, others)

DEA Schedule III Classification

Controlled Substance Status: Testosterone enanthate is a Schedule III controlled substance

Prescribing Requirements:

• DEA registration required for prescribers
• Written, oral, or electronic prescription permitted
• Maximum 5 refills within 6 months
• New prescription required after 6 months or 5 refills

WADA Prohibited Status

Testosterone enanthate is prohibited at all times (both in-competition and out-of-competition) under:

• Category S1: Anabolic Agents
• Subcategory: Exogenous anabolic androgenic steroids

Detection: Testosterone/epitestosterone ratio >4:1 triggers investigation

International Regulatory Status

11. Product Cross-Reference (Compounding vs Brand)

Brand Name Products

Delatestryl (Discontinued in US)

Concentration: 200 mg/mL Vehicle: Sesame oil Status: Brand discontinued but generic equivalents available

Xyosted (Antares Pharma)

Concentrations: 50 mg, 75 mg, 100 mg per 0.5 mL Presentation: Single-dose autoinjector Vehicle: Sesame oil Advantages:

• Convenient once-weekly subcutaneous self-administration
• Reduced injection pain
• Consistent dosing Disadvantages: Higher cost than generic IM

Generic Products

Manufacturers: Eugia USA LLC, others

Formulation: Intramuscular testosterone enanthate injection, USP, Schedule III controlled substance

Vehicle: Typically sesame oil or cottonseed oil

Cost: Significantly less expensive than Xyosted

Compounded Testosterone Enanthate

Source: 503A or 503B compounding pharmacies

Customization Options:

• Custom concentrations (50 mg/mL, 250 mg/mL, etc.)
• Alternative carriers (MCT oil, grapeseed oil, sesame oil, others)
• Preservative-free formulations
• Smaller or larger vial sizes

Quality Considerations: Variable quality between compounders; still Schedule III controlled substance requiring DEA registration

Cost: Variable; often competitive with generics

Comparison Matrix

12. Monitoring & Lab Values

Pre-Treatment Evaluation

Hormonal Panel

• Total Testosterone: Two morning samples (8-10 AM) showing levels <300 ng/dL
• Free Testosterone: If total testosterone borderline
• SHBG: To calculate bioavailable testosterone
• LH and FSH: To distinguish primary vs secondary hypogonadism
• Estradiol: Baseline (optional)
• Prolactin: If secondary hypogonadism suspected

Complete Blood Count (CBC)

• Hemoglobin and hematocrit baseline
• Rule out pre-existing polycythemia

Prostate Assessment

• PSA should be measured in men over 40 years prior to commencement
• Digital rectal exam (DRE)

Metabolic Panel

• Lipid panel
• Comprehensive metabolic panel (CMP)
• Hemoglobin A1c (if diabetic/at risk)

On-Treatment Monitoring Schedule

First 6-12 Months

Your doctor should order fasting morning Total Testosterone, CBC (Hematocrit), and PSA at 3 and 6 months after starting TRT.

Monitoring at 3, 6, and 12 months:

1. Testosterone Levels:

   • Total and free testosterone
   • Measured at trough (day 7 for weekly injections; pre-injection)
   • Target: 400-700 ng/dL

2. Hematologic:

   • CBC with hemoglobin and hematocrit
   • Notify provider if hematocrit >54% or hemoglobin >17.5 g/dL

3. Prostate:

   • PSA at least annually and likely every 6 months
   • Rapid rise or PSA >4 ng/mL warrants evaluation

4. Metabolic:

   • Lipid panel
   • Liver function tests
   • Blood pressure monitoring

5. Optional:

   • Estradiol (if symptoms of excess aromatization)

After First Year (Annual Monitoring)

• Total testosterone (trough)
• CBC with hemoglobin/hematocrit
• PSA
• Lipid panel
• CMP
• Blood pressure
• Bone density scan (if osteoporosis risk)

Intervention Thresholds

Many groups intervene when hematocrit approaches about 54% - for example, the AUA Testosterone Deficiency Guideline describes this threshold.

Actions at Hematocrit ≥54%:

• Dose reduction
• Temporary hold
• Therapeutic phlebotomy

Bloodwork Impact & Monitoring

This section provides detailed guidance on how testosterone enanthate affects laboratory markers, what changes to expect, and how to interpret results in clinical context.

Expected Marker Changes on TRT

Testosterone Level Interpretation

Measuring at the Right Time

For Weekly Injections (IM or SQ):

• Draw blood at TROUGH (day 6-7, just before next injection)
• This provides the lowest testosterone level in the cycle
• Target trough: 400-500 ng/dL minimum

For Xyosted (Weekly SQ):

• Same as above; draw day 7, before next dose

For Biweekly IM Injections:

• Draw at mid-cycle (day 7-10) OR trough (day 13-14)
• Expect wider fluctuations

Time of Day:

• Morning draw preferred (8-10 AM) for consistency
• Testosterone has diurnal variation even on TRT
• Fasting preferred for lipids, glucose

Testosterone Level Targets by Goal

Estradiol (E2) Management

Expected Ranges:

Low E2 Symptoms:

• Joint pain/stiffness
• Low libido paradoxically
• Mood issues (anxiety, depression)
• Dry skin
• Erectile dysfunction

High E2 Symptoms:

• Gynecomastia (breast tenderness/growth)
• Water retention/bloating
• Mood swings, emotional lability
• Decreased libido
• Erectile dysfunction

Hematocrit Monitoring Protocol

Critical Safety Marker: Polycythemia (elevated hematocrit) is the most common adverse effect of TRT and requires vigilant monitoring.

Factors Increasing Polycythemia Risk:

• Older age (>50)
• Higher testosterone doses
• IM injection (vs SQ)
• Sleep apnea
• Smoking
• Living at high altitude
• Baseline elevated Hct

Management Strategies:

1. Dose reduction: Decrease by 20-25%
2. Split dosing: More frequent, smaller doses (e.g., 2x/week vs weekly)
3. Route change: SQ often causes less elevation than IM
4. Therapeutic phlebotomy: Remove 1 unit (500mL) of blood; repeat as needed
5. Hydration: Ensure adequate fluid intake
6. Aspirin: Low-dose aspirin may reduce thrombotic risk (discuss with physician)

PSA Monitoring Protocol

Note: PSA can rise on TRT due to prostate volume increase; this does not necessarily indicate cancer but requires evaluation.

Lipid Panel Interpretation

Red Flags in Labs - Immediate Action Required

Labs + Symptoms Integration

Comprehensive Bloodwork Protocol Summary

Baseline (Before Starting TRT)

Required:

• Total Testosterone (2 morning draws)
• Free Testosterone
• Estradiol (sensitive)
• SHBG
• LH, FSH
• CBC with differential
• PSA (men >40)
• CMP (liver, kidney function)
• Lipid Panel

Recommended:

• Prolactin (if secondary hypogonadism)
• TSH, Free T4
• Vitamin D 25-OH
• HbA1c (if diabetic risk)

6-8 Weeks (First Follow-Up)

Required:

• Total Testosterone (trough)
• Estradiol (sensitive)
• CBC (hematocrit focus)
• PSA

3 Months

Required:

• Total Testosterone (trough)
• CBC
• PSA
• Estradiol

Optional:

• Lipid Panel
• Free Testosterone

6 Months

Full Panel:

• Total Testosterone (trough)
• Free Testosterone
• Estradiol (sensitive)
• SHBG
• CBC
• PSA
• CMP
• Lipid Panel

Ongoing (Every 3-6 Months Stable; Annually Comprehensive)

Minimum (Every 3-6 Months):

• Total Testosterone (trough)
• CBC
• PSA

Annual Comprehensive:

• All above plus CMP, Lipid Panel, SHBG, Free T
• DEXA scan if osteoporosis risk
• DRE (digital rectal exam) for men >40

13. Drug Interactions & Contraindications - Comprehensive

This section provides detailed drug interaction information for testosterone enanthate, organized by drug class with specific management recommendations.

Anticoagulants

Key Reference: FDA Package labeling (Delatestryl) documents warfarin interaction; INR monitoring is standard of care.

Clinical Pearl: The interaction develops gradually over 2-4 weeks as testosterone reaches steady state. More frequent monitoring needed with any TRT dose change.

Diabetes Medications

Clinical Note: Testosterone's metabolic benefits can improve glycemic control over 3-6 months. Proactive medication adjustments prevent hypoglycemia. Patients with Type 2 diabetes may see HbA1c improvements of 0.3-0.6% independent of medication changes.

Cardiovascular Medications

Thyroid Medications

Clinical Pearl: Patients often report improved energy that may be mistakenly attributed to testosterone when thyroid levels are actually optimizing.

Psychiatric Medications

Hormone-Related Medications

Pain and Anti-inflammatory Medications

Other Prescription Medications

Supplements Interactions

Food and Timing Interactions

Testosterone Enanthate vs Cypionate: Interaction Profile Comparison

Clinical Note: Once the ester is cleaved, both compounds release bioidentical testosterone, making their drug interaction profiles essentially identical.

Drug Interaction Summary Table

Absolute Contraindications

1. Known or Suspected Prostate Cancer: Testosterone may stimulate tumor growth
2. Known or Suspected Breast Cancer in Males: Androgen-responsive tumors
3. Pregnancy: Category X; causes virilization of female fetus
4. Serious Cardiac, Hepatic, or Renal Dysfunction: May be exacerbated by fluid retention
5. Known hypersensitivity to testosterone or sesame oil (for Xyosted and most generics)

Relative Contraindications

1. Benign Prostatic Hyperplasia (BPH) with Severe Symptoms: May worsen urinary obstruction
2. Untreated Severe Obstructive Sleep Apnea: Testosterone may worsen
3. Hematocrit >50%: Risk of further elevation
4. Uncontrolled Heart Failure: Fluid retention risk
5. Recent MI or Stroke (within 6 months): Increased cardiovascular risk
6. Desire for Fertility (without HCG): Testosterone suppresses spermatogenesis
7. Active or recent venous thromboembolism: Polycythemia increases clot risk

Precautions

Geriatric Use: Elderly patients are more likely to have prostate problems and cardiovascular disease; start low, titrate slow

Pediatric Use: Generally not used in children except for delayed puberty; risk of premature epiphyseal closure

Hepatic Impairment: Use with caution; monitor liver function tests

Renal Impairment: Use with caution; edema risk

Polycythemia vera: Contraindicated; will worsen condition

Protocol Integration

This section describes how testosterone enanthate integrates with other compounds commonly used in optimization protocols. Understanding synergies, timing, and monitoring considerations enables more effective multi-compound strategies.

Stacking with HCG (Human Chorionic Gonadotropin)

Rationale: HCG mimics LH, maintaining testicular function and fertility during TRT. Without HCG, exogenous testosterone suppresses the HPTA, causing testicular atrophy and azoospermia.

Common Protocols:

Timing Considerations:

• HCG can be injected on the same day as testosterone or on alternate days
• Some protocols prefer HCG 24-48 hours after T injection
• Subcutaneous injection of HCG is effective and well-tolerated

Monitoring Additions:

• Estradiol may rise more with HCG (HCG stimulates intratesticular aromatase)
• Check E2 at 6-8 weeks after adding HCG
• Semen analysis if fertility is the goal

Clinical Pearl: HCG monotherapy can maintain testosterone levels in some men; combination with TRT ensures both exogenous T delivery and testicular function.

Stacking with Aromatase Inhibitors (AI)

Rationale: Testosterone aromatizes to estradiol; some men develop elevated E2 with symptoms. AIs block this conversion.

Common AI Protocols:

When to Add AI:

• E2 >50-60 pg/mL WITH symptoms (gynecomastia, water retention, mood issues)
• Do NOT add AI prophylactically based on labs alone
• Some men tolerate E2 70-80 pg/mL without symptoms

Monitoring:

• Check E2 4-6 weeks after starting/adjusting AI
• Target E2: 20-40 pg/mL typically
• Watch for symptoms of LOW E2 (joint pain, low libido, mood)

Critical Warning: AI overcorrection (E2 <15 pg/mL) causes significant side effects including:

• Joint pain and stiffness
• Loss of libido
• Depression and anxiety
• Erectile dysfunction
• Bone density loss (long-term)

Stacking with Growth Hormone Peptides

Rationale: GH peptides (Ipamorelin, CJC-1295, Tesamorelin, MK-677) enhance body composition, recovery, and longevity outcomes when combined with TRT.

Common Stacks:

Timing Considerations:

• GH peptides work best fasted or 2+ hours after eating
• Bedtime dosing aligns with natural GH pulse
• MK-677 can be taken with or without food
• Testosterone timing not affected by peptide dosing

Monitoring Additions:

• IGF-1 levels (target 150-250 ng/mL; avoid >300)
• Fasting glucose and HbA1c (GH peptides can raise glucose)
• Watch for fluid retention (additive with testosterone)

Clinical Pearl: This combination is particularly effective for body recomposition goals, with TRT providing the anabolic foundation and GH peptides enhancing fat loss and recovery.

Stacking with GLP-1 Agonists

Rationale: GLP-1 agonists (semaglutide, tirzepatide) and testosterone have synergistic metabolic effects, making this combination highly effective for body recomposition.

Protocol Notes:

No Pharmacokinetic Interaction: GLP-1 agonists do not affect testosterone absorption or metabolism.

Clinical Considerations:

• Start GLP-1 at low dose and titrate slowly (nausea common)
• Protein intake critical (both promote lean mass; ensure adequate substrate)
• Monitor for hypoglycemia if on diabetes medications (may need reduction)
• Weight loss with muscle preservation is the ideal outcome

Monitoring:

• Standard TRT monitoring
• Metabolic panel (glucose, HbA1c, lipids)
• Body composition assessment (if available)

Stacking with BPC-157 and TB-500 (Healing Peptides)

Rationale: Testosterone supports tissue repair; healing peptides (BPC-157, TB-500) may accelerate recovery from injuries.

Protocol Integration:

Notes:

• No known interaction between testosterone and BPC-157/TB-500
• Testosterone provides anabolic support; peptides provide tissue-specific healing
• Adequate testosterone levels are prerequisite for optimal healing response
• Consider stacking with GH peptides for enhanced recovery

Monitoring:

• Standard TRT monitoring
• Clinical assessment of injury healing
• No additional labs typically needed for peptides

Stacking with Thyroid Medications

Rationale: Hypothyroidism and hypogonadism frequently coexist; optimizing both is essential for full symptom resolution.

Protocol Notes:

• Testosterone may decrease thyroxine-binding globulin (TBG)
• Monitor Free T4 (more reliable than Total T4 on TRT)
• Some patients require levothyroxine dose adjustment after starting TRT

Timing:

• Levothyroxine: Take in morning, 30-60 minutes before food
• Testosterone: Any time of day; no interaction with levothyroxine timing
• Separate by 4+ hours from calcium, iron, or other supplements that affect thyroid absorption

Monitoring:

• Free T4 and TSH at baseline, 6-8 weeks, and 3 months after starting TRT
• Adjust levothyroxine based on Free T4 (not Total T4)

Common Multi-Compound Stacks

Body Recomposition Stack

Longevity/Anti-Aging Stack

Healing/Recovery Stack

Integration with Lifestyle Pillars

Pharmacokinetic Comparison: Enanthate vs Cypionate in Stacking

Bottom Line: Once the ester is cleaved, both release identical bioidentical testosterone. Stacking protocols, monitoring, and outcomes are essentially the same regardless of ester choice.

14. References & Citations

Primary Research Articles

1. Testosterone Enanthate - PubChem
2. Testosterone enanthate - Chemical Book
3. Testosterone enanthate - Wikipedia
4. Androgen Replacement - NCBI StatPearls

Regulatory Documents

5. Delatestryl Label - FDA 2016
6. Federal Register: Determination That DELATESTRYL Was Not Withdrawn for Safety (2024)
7. XYOSTED Label - FDA DailyMed
8. XYOSTED Label 2025 Update - FDA

Clinical Trials & Safety Studies

9. Secondary Polycythemia in Men Receiving TRT Increases Risk of MACE and VTE - PubMed 2022
10. Secondary Polycythemia MACE/VTE Risk - Journal of Urology 2022
11. Testosterone therapy-induced erythrocytosis 2024
12. Prevalence and predictive factors of testosterone-induced erythrocytosis 2024
13. Post-market safety and efficacy of Xyosted 2021

Clinical Guidelines

14. Testosterone Therapy in Men With Hypogonadism: Endocrine Society Guideline 2018
15. Society for Endocrinology guidelines 2022
16. Testosterone Deficiency Guideline - AUA
17. Treatment of male hypogonadism with testosterone enanthate - PubMed 1983

Comparative Studies

18. Testosterone Cypionate vs Enanthate Comparison - NRG Clinic
19. Testosterone Enanthate vs Cypionate Guide - Swolverine
20. Testosterone enanthate vs cypionate differences - Single Care
21. Testosterone Cypionate vs Enanthate - LifeWell MD
22. Testosterone Cypionate vs Enanthate - TestoDepot

Xyosted Information

23. FDA Clears First Autoinjectable Testosterone - Medscape 2018
24. New FDA Approval: Subcutaneous Testosterone Pen
25. XYOSTED Official Site
26. Xyosted Drug Information - RxList

Monitoring & Lab Testing

27. [Table 7: Follow-up Laboratory Testing - AUA](https://www.auanet.org/documents/Guidelines/PDF/Table Seven - Follow-up Laboratory Testing(0).pdf)
28. How to Monitor TRT Lab Tests - Discounted Labs
29. TRT Blood Work Tests - Discounted Labs
30. Critical Role of Lab Testing in TRT - PRCPB
31. Testosterone and Polycythemia - AUA News
32. Predictive factors for elevated PSA and hematocrit - JOMH
33. Testosterone Injection Dosage Chart - PeakStack

Storage & Stability

34. Testosterone Shelf Life - Live Forever Lab
35. Does Testosterone Need Refrigeration - 4AllFamily
36. Expired Testosterone Guide - TRT Hub
37. Comprehensive Analysis of Testosterone Carrier Oils - Excel Male
38. MCTs vs Seed Oil in Injectable TRT - Maximus Tribe
39. Testosterone Expiration for Opened Vials - Excel Male

General References

40. TRT Essential Guide 2024 - Enhanced Men's Clinic
41. Testosterone Dosage Guide - Drugs.com
42. Delatestryl Package Insert - Drugs.com

Document Prepared By: Research Team, Epiq Aminos Project: HRT Research Papers - 76 Topic Series Paper: 2 of 76 Date: December 2024